CTIS2024-513086-39-00进行中（未招募）1 期
A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101 - AVXS-101-LT-002
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 131
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Any patient with SMA who received AVXS-101 gene replacement therapy in a Novartis Pharma AG -sponsored clinical study, Patient/parent/legal guardian willing and able to complete the informed consent process and comply with study procedures and visit schedule
排除标准
- •Patient/parent/legal guardian unable or unwilling to participate in the long-term follow-up safety study
研究者
相似试验
招募中
1 期
ot applicableMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2019-002611-26-ITAVEXIS, INC.308
进行中（未招募）
1 期
ot applicableSpinal Muscular AtrophyEUCTR2019-002611-26-GBAveXis, Inc.308
进行中（未招募）
1 期
ot applicableSpinal Muscular AtrophyEUCTR2019-002611-26-BEovartis Gene Therapies, Inc.308
进行中（未招募）
1 期
ot applicableSpinal Muscular AtrophyEUCTR2019-002611-26-FRAveXis, Inc.308
进行中（未招募）
1 期
ot applicableSpinal Muscular AtrophyEUCTR2019-002611-26-ESAveXis, Inc.308